SCHEMBL10112430

SCHEMBL10112430

c1ccc(-c2nnc(-c3cccc(-c4c5ccccc5c(-c5cccc(-c6nnc(-c7ccccc7)o6)c5)c5cc(N(c6ccccc6)c6ccc(N(c7ccccc7)c7ccccc7)cc6)ccc45)c3)o2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 15/20 0.46
RAB9A P51151 15/20 0.46
SMN1; SMN2 Q16637 10/20 0.46
HPGD P15428 6/20 0.46
TSHR P16473 5/20 0.46
TP53 P04637 3/20 0.46
NFKB1 P19838 2/20 0.46
NFKB2 Q00653 2/20 0.46
RELA Q04206 2/20 0.46
MECP2 P51608 1/20 0.46
ALDH1A1 P00352 7/20 0.41
MAPT P10636 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
CA13 Q8N1Q1 1/20 0.41
ATAD2 Q6PL18 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21090317 0.93 NPC1 (0.49) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL10112429 0.92 NPC1 (0.47) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL19953893 0.92 RAB9A (0.46) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL10112679 0.89 NPC1 (0.37) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL10112568 0.88 NPC1 (0.37) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL10112436 0.86 RAB9A (0.44) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL10112434 0.85 NPC1 (0.42) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL19953863 0.85 NPC1 (0.42) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL173683 0.84 NPC1 (0.59) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL14466355 0.84 NPC1 (0.59) NPC1RAB9ASMN1; SMN2HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
US-8110980-B2 Anthracene derivative, and light emitting element, light emitting device, electronic device using anthracene derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2012-02-07 US disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-20100164376-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2010-07-01 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
US-7674914-B2 novel anthracene derivative represented by General Formula (1) is provided, which enables the production of a light-emitting element with high luminous efficiency and a long lifetime. A high-performance light-emitting device and electronic device in which the anthracene derivative light emitting diode SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2010-03-09 US disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. 2008-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103315-A1 Anthracene Derivative, and Light Emitting Element, Light Emitting Device, Electronic Device Using Anthracene Derivative AMY1A, CYP1A1, CRY1 NPC1 3526/4885RAB9A 2483/4885SMN1; SMN2 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.